Thrombolysis and thrombectomy in patients treated with dabigatran with acute ischemic stroke: Expert opinion
Date
2017Language
en
Keyword
Abstract
Systemic thrombolysis with rt-PA is contraindicated in patients with acute ischemic stroke anticoagulated with dabigatran. This expert opinion provides guidance on the use of the specific reversal agent idarucizumab followed by rt-PA and/or thrombectomy in patients with ischemic stroke pre-treated with dabigatran. The use of idarucizumab followed by rt-PA is covered by the label of both drugs. © 2016, © 2016 World Stroke Organization.
Collections
Related items
Showing items related by title, author, creator and subject.
-
Effectiveness and safety of intracranial events associated with the use of direct oral anticoagulants for atrial fibrillation: A systematic review and meta-analysis of 92 studies
Archontakis-Barakakis P., Li W., Kalaitzoglou D., Tzelves L., Manolopoulos A., Giannopoulos S., Giamouzis G., Giannakoulas G., Batsidis A., Palaiodimos L., Ntaios G., Lip G.Y.H., Kokkinidis D.G. (2022)Aims: Observational studies have investigated the effectiveness and safety of direct oral anticoagulants (DOACs) and vitamin K antagonists (VKAs) used in nonvalvular atrial fibrillation. We performed a systematic review ... -
Real-World Setting Comparison of Nonvitamin-K Antagonist Oral Anticoagulants Versus Vitamin-K Antagonists for Stroke Prevention in Atrial Fibrillation: A Systematic Review and Meta-Analysis
Ntaios G., Papavasileiou V., Makaritsis K., Vemmos K., Michel P., Lip G.Y.H. (2017)Background and Purpose - Evidence from the real-world setting complements evidence coming from randomized controlled trials. We aimed to summarize all available evidence from high-quality real-world observational studies ... -
Early recurrence and major bleeding in patients with acute ischemic stroke and atrial fibrillation treated with Non-Vitamin-K oral anticoagulants (RAF-NOACs) Study
Paciaroni M., Agnelli G., Falocci N., Tsivgoulis G., Vadikolias K., Liantinioti C., Chondrogianni M., Bovi P., Carletti M., Cappellari M., Zedde M., Ntaios G., Karagkiozi E., Athanasakis G., Makaritsis K., Silvestrelli G., Lanari A., Ciccone A., Putaala J., Tomppo L., Tatlisumak T., Abdul-Rahim A.H., Lees K.R., Alberti A., Venti M., Acciarresi M., D'Amore C., Becattini C., Mosconi M.G., Cimini L.A., Soloperto R., Masotti L., Vannucchi V., Lorenzini G., Tassi R., Guideri F., Acampa M., Martini G., Sohn S.-I., Marcheselli S., Mumoli N., De Lodovici M.L., Bono G., Furie K.L., Tadi P., Yaghi S., Toni D., Letteri F., Tassinari T., Kargiotis O., Lotti E.M., Flomin Y., Mancuso M., Maccarrone M., Giannini N., Bandini F., Pezzini A., Poli L., Padovani A., Scoditti U., Denti L., Consoli D., Galati F., Sacco S., Carolei A., Tiseo C., Gourbali V., Orlandi G., Giuntini M., Chiti A., Giorli E., Gialdini G., Corea F., Ageno W., Bellesini M., Colombo G., Monaco S., Baronello M.M., Karapanayiotides T., Caso V. (2017)Background--The optimal timing to administer non-vitamin K oral anticoagulants (NOACs) in patients with acute ischemic stroke and atrial fibrillation is unclear. This prospective observational multicenter study evaluated ...